Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

1.Permira Holdings Limited ("Permira") and Sestant Internazionale S.p.A. ("Sestant") intend to indirectly acquire joint control over Kedrion S.p.A. ("Kedrion") and Bio Products Laboratory Holdings Limited ("BPL", together with Kedrion, the "Targets") through acquisition of all shares in the Targets by an investment vehicle which will be ultimately jointly controlled by Permira and Sestant.

2.Permira, with registered seat in Guernsey, is a European private equity firm which makes long-term private equity investments in companies active in a wide variety of sectors that have potential for growth and development.

3.Sestant, with registered seat in Italy, is a financial holding company primarily committed to overseeing the international assets of the Marcucci family.

4.Kedrion is the parent company of an Italy based global biopharmaceutical group specializing in the collection of human plasma and the development, production and sale of therapeutic plasma-derived products.

5.Headquartered in Elstree, the UK, and with plasma collection centres across the US, BPL is dedicated to producing a range of plasma-derived products for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well as for critical care.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.